Medical Representative Off-Label Push: When Manufacturer “Joint” Risk Becomes Real

Life Sciences & Healthcare Blog · Legal cluster hub

Physicians may use products off-label. Manufacturers create a different problem when field force incentives and leave-behinds effectively sell unapproved indications. This article explains how medical representative off-label promotion creates joint risk for the manufacturer, the statutory basis for employer vicarious liability, and the governance controls that survive inspection.

Where joint-risk narratives come from#

Off-label use is a clinical reality that the law accommodates under strict conditions. The problem for the manufacturer begins when its own field force sells the off-label use. The risk does not require a formal marketing campaign; it is built from the everyday artefacts of the sales function: a detailing aid that references an unapproved indication, a WeChat file that a representative sends to a physician, an incentive scheme that rewards indication share outside the approved label, a medical science liaison deck that names a dosing regimen beyond the label, and silence after repeated off-label complaints that reach medical affairs. Each artefact is individually small, and together they create the narrative that the manufacturer promoted the unapproved use.

The enforcement logic is attribution. The manufacturer controls the field force, the field force touches the physician, and the physician's prescribing behaviour shifts toward the unapproved use. The authority does not need to prove that the manufacturer explicitly instructed the off-label promotion; it needs to show that the manufacturer created the conditions, rewarded the behaviour and failed to correct it. That is the joint-risk narrative, and it is difficult to defend once the evidence trail exists.

Statutory framework#

Pharmaceutical representative rules#

The Provisions on the Record-filing Management of Pharmaceutical Representatives, issued on a trial basis in 2020, directly govern the conduct of medical representatives. Article 12 prohibits representatives from engaging in off-label promotion, from providing gifts or other benefits to physicians, and from other conduct that violates the drug administration and advertising rules. The provision is the direct regulatory basis for the off-label prohibition, and it also creates the record-filing system that makes representatives traceable to their employers. The employer that cannot produce the representative's filing record, or that allows a representative to operate without filing, has already created an inspection finding.

Anti-Unfair Competition Law#

The PRC Anti-Unfair Competition Law Article 7 prohibits commercial bribery, and the vicarious reach of the provision is the second pillar of the joint-risk framework. Where a representative pays or benefits a physician to prescribe an unapproved indication, the conduct is bribery attributable to the manufacturer if the representative acted within the scope of employment or with the manufacturer's benefit in mind. The manufacturer's defence that the representative acted independently is weak where the incentive scheme rewarded the very behaviour that produced the bribe.

Physician Law#

The PRC Physician Law Article 29 restricts off-label drug use by physicians, requiring that off-label use be based on sufficient evidence, that the physician inform the patient, and that the use be supervised within the institution. The provision matters for the manufacturer because it defines the legitimate clinical pathway for off-label use: evidence-based, patient-informed and institutionally supervised. The manufacturer that promotes off-label use outside this pathway is promoting conduct that even the clinician cannot lawfully perform.

Civil Code employer liability#

The PRC Civil Code Article 1191 provides that where an employee causes damage in the performance of work duties, the employer bears liability, and the employer may recover from the employee who acted intentionally or with gross negligence. The provision is the tort law anchor for the manufacturer's exposure to the off-label conduct of its representatives. The same logic applies in the regulatory and criminal contexts, where the employer's control over the field force is the basis for attributing the representative's conduct to the company.

Enforcement context: the Shanghai AMR off-label case#

A 2022 administrative fine issued by the Shanghai Administration for Market Regulation penalized a pharmaceutical manufacturer for off-label promotional lectures delivered by its medical representatives. The company defended by arguing that the representatives acted independently and that the lectures were not part of the company's approved promotional program. The authority rejected the defence, finding that the representatives were acting within the scope of their employment, that the materials used in the lectures were traceable to the company, and that the company's incentive structure rewarded the off-label selling behaviour. The case is the enforcement template: the authority does not need a formal campaign, and the defence of independent action fails where the employer controlled, rewarded or tolerated the conduct.

Controls that survive inspection#

The practical deliverable is a set of governance controls that are enforcement-tested. The controls have four components.

MR code of conduct agreements#

Every representative should sign a code of conduct agreement that expressly prohibits off-label promotion, gift-giving and improper benefits, and that references the 2020 provisions. The agreement should be part of the employment or contractor file, should be re-signed annually, and should be paired with training that explains the consequences of violation. The agreement alone is not a defence, but its absence is an immediate inspection finding.

Medical information unsolicited request forms#

When physicians request medical information beyond the label, the company should route the request through a controlled channel: the medical information request form, answered by the medical function with materials approved for unsolicited requests. The form creates the documentation that the company responded to unsolicited inquiries appropriately rather than promoted the unapproved use. The sales function must not answer the requests, and the form should be retained as evidence of the boundary between compliant medical information and prohibited promotion.

Incentive structure compliance reviews#

The incentive scheme is the root cause of most off-label promotion. The compliance function should review the scheme before it is implemented, and the review should test whether the scheme rewards indication share, prescribing volume for unapproved uses or outcomes that can only be achieved through off-label selling. The review should be documented, and the scheme should be adjusted where the test fails. The incentive review is the control that the authority examines when deciding whether the off-label conduct was a rogue action or a systemic pattern.

Labor-law compliant dismissal procedures#

When a representative is found to have engaged in off-label promotion, the company must decide whether to discipline or dismiss, and the decision must follow the labor law process. The dismissal should be based on documented rules, should include the union notification where required, and should be supported by the evidence of the violation. A dismissal that skips the process converts the compliance action into a labor claim, and the labor claim can become the vehicle through which the off-label evidence enters the public record.

Building the defence file#

The manufacturer's defence to an off-label enforcement case rests on the contemporaneous record. The defence file should show that the company trained the field force on the prohibition, that the materials were version-controlled and approved, that the incentive scheme was reviewed and adjusted, that the off-label complaints were escalated and answered, and that violations were disciplined. The file should also show the rapid quarantine of rogue materials: when a representative distributes an unapproved PDF, the company should identify it, remove it from the field and document the removal. The discipline files are the evidence that the company did not ratify the misconduct, and they are the difference between a rogue-action defence and a systemic-pattern finding.

The audit function should include mystery-shop style reviews: compliance personnel or external auditors posing as physicians and observing the representative's presentation. The mystery-shop findings should be fed back into the training and the incentive review, and the recurring patterns should be escalated to the compliance committee. The audit is the operational engine that makes the defence file credible, because it shows that the company actively tested its own controls rather than waiting for the enforcement authority to do so.

The off-label and anti-bribery interface#

Off-label promotion and improper benefits often travel together, and the compliance program should treat them as one risk. A representative who sells an unapproved indication is likely also paying for the access, and the payment is the bribery component that attracts the criminal law. The controls should therefore be integrated: the code of conduct covers both, the training covers both, and the investigation of a complaint covers both. The company that treats off-label promotion as a pure advertising problem misses the bribery dimension, and the bribery dimension is the one that turns an administrative matter into a criminal case.

The digital channel adds a dimension that the classic controls do not address. Medical representatives in China communicate with physicians primarily through WeChat, and the off-label materials travel as PDFs, screenshots and links in private chats that are outside the company's marketing systems. The compliance program should include a digital monitoring component: sampling of the field communication channels where permitted by law and employment policy, a rapid quarantine procedure for off-label files that appear in circulation, and a documented escalation path when a representative's digital materials exceed the label. The employment contract and the code of conduct should expressly authorize the company to review the work-related communication channels and to discipline misuse, because without that authorization the monitoring creates its own labor law exposure. The digital monitoring program should also cover the KOL engagement channel, because a medical science liaison deck that is approved for science but names off-label dosing is the same risk in a different wrapper. By extending the controls to the digital field, the company closes the channel through which most off-label promotion actually occurs.

Read next: Pharma advertising · Labeling & ADR · Anti-corruption

Part of the life sciences legal cluster · Life sciences blog